Vaccine (Peptide vaccine) · Immune activation
IMA970A is a multi-peptide therapeutic vaccine of sixteen peptides derived from tumor-associated antigens expressed by liver cancer cells, given intradermally. The liver-specific peptides are designed to activate CD4+ T-helper and CD8+ cytotoxic T-lymphocyte responses against hepatocellular carcinoma cells. It is studied in hepatocellular carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03203005 | Phase 1/2 | Hepatocellular Carcinoma | Completed | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hepatocellular Carcinoma